JP2021506821A5 - - Google Patents

Info

Publication number
JP2021506821A5
JP2021506821A5 JP2020532928A JP2020532928A JP2021506821A5 JP 2021506821 A5 JP2021506821 A5 JP 2021506821A5 JP 2020532928 A JP2020532928 A JP 2020532928A JP 2020532928 A JP2020532928 A JP 2020532928A JP 2021506821 A5 JP2021506821 A5 JP 2021506821A5
Authority
JP
Japan
Prior art keywords
benzazepine
triazolo
chloro
trans
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020532928A
Other languages
English (en)
Japanese (ja)
Other versions
JP7428647B2 (ja
JP2021506821A (ja
Filing date
Publication date
Priority claimed from HU1700521A external-priority patent/HU231206B1/hu
Application filed filed Critical
Publication of JP2021506821A publication Critical patent/JP2021506821A/ja
Publication of JP2021506821A5 publication Critical patent/JP2021506821A5/ja
Application granted granted Critical
Publication of JP7428647B2 publication Critical patent/JP7428647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020532928A 2017-12-15 2018-12-14 バソプレシンV1a受容体拮抗薬としてのトリアゾロベンズアゼピン Active JP7428647B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1700521 2017-12-15
HU1700521A HU231206B1 (hu) 2017-12-15 2017-12-15 Triazolobenzazepinek
PCT/IB2018/060077 WO2019116324A1 (en) 2017-12-15 2018-12-14 Triazolobenzazepines as vasopressin v1a receptor antagonists

Publications (3)

Publication Number Publication Date
JP2021506821A JP2021506821A (ja) 2021-02-22
JP2021506821A5 true JP2021506821A5 (https=) 2023-04-25
JP7428647B2 JP7428647B2 (ja) 2024-02-06

Family

ID=89992589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020532928A Active JP7428647B2 (ja) 2017-12-15 2018-12-14 バソプレシンV1a受容体拮抗薬としてのトリアゾロベンズアゼピン

Country Status (23)

Country Link
US (1) US11298363B2 (https=)
EP (1) EP3724192B1 (https=)
JP (1) JP7428647B2 (https=)
KR (1) KR102719165B1 (https=)
CN (1) CN111479813B (https=)
AR (1) AR113933A1 (https=)
AU (1) AU2018385724B2 (https=)
BR (1) BR112020011880A2 (https=)
CA (1) CA3085562A1 (https=)
CL (1) CL2020001564A1 (https=)
CU (1) CU24630B1 (https=)
EA (1) EA202091344A1 (https=)
HU (1) HU231206B1 (https=)
IL (1) IL275084B2 (https=)
JO (1) JOP20200149B1 (https=)
MX (1) MX2020006204A (https=)
PE (1) PE20210671A1 (https=)
PH (1) PH12020500548A1 (https=)
SG (1) SG11202005299VA (https=)
TN (1) TN2020000083A1 (https=)
TW (1) TWI826406B (https=)
UA (1) UA129516C2 (https=)
WO (1) WO2019116324A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2022018121A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists
TWI804119B (zh) * 2020-12-21 2023-06-01 大陸商上海濟煜醫藥科技有限公司 三氮唑類三并環衍生物及其製備方法和應用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382185B1 (en) 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
EP1097920B1 (en) 1993-07-21 2004-09-22 Yamanouchi Pharmaceutical Co. Ltd. Intermediate for condensed benzazepine derivatives
ES2284741T3 (es) 1994-06-15 2007-11-16 Otsuka Pharmaceutical Company, Limited Derivados de benzoheterociclicos utilizados como moduladores de vasoprsinao de oxitocina.
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
SK16242002A3 (sk) 2000-05-19 2003-04-01 Merck Patent Gmbh Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje
US7001898B2 (en) 2000-07-05 2006-02-21 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
US7056910B2 (en) 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
MXPA04003358A (es) 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
KR100750028B1 (ko) * 2003-02-19 2007-08-16 화이자 인코포레이티드 치료에 유용한 트리아졸 화합물
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
EA010132B1 (ru) 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
CA2593044A1 (en) 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
CA2602194A1 (en) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
ES2434467T3 (es) 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
CA2615726C (en) 2005-07-14 2014-05-27 Caterina Bissantz Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
KR100984893B1 (ko) 2005-07-21 2010-10-01 에프. 호프만-라 로슈 아게 V1a 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체
EP2392571A3 (en) 2005-07-29 2012-03-14 F. Hoffmann-La Roche AG Indol-3-yl-carbonyl-piperidin and piperazin derivatives
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
JP2010517966A (ja) 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
TW201103907A (en) 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands
SG10201406839VA (en) 2009-10-26 2014-12-30 Otsuka Pharma Co Ltd Benzazepine compound
GB201004677D0 (en) 2010-03-19 2010-05-05 Vantia Ltd New salt
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
EP2569280B1 (en) 2010-05-11 2015-02-25 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
US20130237530A1 (en) * 2010-11-15 2013-09-12 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
EP2900672B1 (de) * 2012-09-28 2017-02-22 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
CN106349241B (zh) * 2015-07-15 2020-04-21 上海翰森生物医药科技有限公司 具有hsp90抑制活性的三唑衍生物及其制备方法和应用
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof

Similar Documents

Publication Publication Date Title
JP2021506821A5 (https=)
IL275084B2 (en) Triazolobenzazepines as vasopressin v1a receptor antagonists
RU2439062C2 (ru) Производные имидазолона и имидазолидинона как 11в-hsd1 ингибиторы при диабете
JP2024525044A5 (https=)
JP4783870B1 (ja) β3アドレナリン受容体アゴニストとしてのヒドロキシメチルピロリジン
JP2022501338A5 (https=)
JP5738871B2 (ja) β3アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法
JP5667684B2 (ja) 関節炎の治療方法
JP5977819B2 (ja) C型肝炎ウイルス阻害剤
RU2012145237A (ru) Производные арилэтинила
JP2021517893A5 (https=)
JP2023552864A5 (https=)
JP2014532660A5 (https=)
WO2014151784A1 (en) Compounds and compositions for the treatment of parasitic diseases
RU2017135520A (ru) Бициклические производные хиназолинона
RU2008141374A (ru) Фармацевтическая композиция, содержащая по крайнер мере один ингибитор ркс и по крайней мере один ингибитор киназы jak3, предназначенная для лечения аутоиммунных нарушений
EP3063142B1 (en) Inhibitors of the renal outer medullary potassium channel
JP2015513552A5 (https=)
JP6111274B2 (ja) 新規ニューロキニン1受容体アンタゴニスト化合物
JP2023539985A5 (https=)
JP2018522929A5 (https=)
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
RU2008119322A (ru) Композиции ингибиторов фосфодиэстеразы iv типа
JP2009514980A5 (https=)
RU2015149832A (ru) СОЕДИНЕНИЯ ПИРАЗИНО[1,2-а]ИНДОЛА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ЛЕКАРСТВЕННЫХ СРЕДСТВАХ